Current Diabetes Reports

, Volume 4, Issue 6, pp 447–454 | Cite as

Transforming growth factor-beta: A clinical target for the treatment of diabetic nephropathy

  • Tracy A. McGowan
  • Yanqing Zhu
  • Kumar Sharma

Abstract

Diabetic nephropathy is continuing to rise in incidence, despite awareness of tight glycemic control and blood pressure. The identification that matrix accumulation is driven by transforming growth factor-â (TGF-â) has led to a concerted effort to apply antifibrotic strategies for this disorder. Recent studies have not only demonstrated the beneficial effects of blocking TGF-â on matrix accumulation but have also found that blocking TGF-â may have important hemodynamic effects that are relevant to diabetic complications. In this article, we review the latest knowledge regarding the role of TGF-â in diabetic kidney disease and discuss available and novel therapeutic approaches. The role of a novel antifibrotic drug, pirfenidone, may have important clinical relevance to diabetic nephropathy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Mauer SM, Steffes MW, Ellis EN, et al.: Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984, 74:1143–1155.PubMedGoogle Scholar
  2. 2.
    Harris RD, Steffes MW, Bilous RW, et al.: Global glomerular sclerosis and glomerular arteriolar hyalinosis in insulin dependent diabetes. Kidney Int 1991, 40:107–114.PubMedGoogle Scholar
  3. 3.
    Ziyadeh FN: The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 1993, 22:736–744.PubMedGoogle Scholar
  4. 4.
    Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-beta as a key mediator. Diabetes 1995, 44:1139–1146.PubMedCrossRefGoogle Scholar
  5. 5.
    McGowan T, McCue P, Sharma K: Diabetic nephropathy. Clin Lab Med 2001, 21:111–146.PubMedGoogle Scholar
  6. 6.
    O’Bryan G, Hostetter T: The renal hemodynamic basis of diabetic nephropathy. Sem Nephrol 1997, 17:93–100.Google Scholar
  7. 7.
    Steffes MW, Osterby R, Chavers B, Mauer SM: Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 1989, 38:1077–1081.PubMedCrossRefGoogle Scholar
  8. 8.
    Strutz F, Muller G: Interstitial pathomechanisms underlying progressive tubulointerstitial damage. Kidney Blood Press Res 1999, 22:71–80.PubMedCrossRefGoogle Scholar
  9. 9.
    Steffes MW, Schmidt D, McCrery R, Basgen JM: Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int 2001, 59:2104–2113. This is a carefully performed study showing that mesangial cell and endothelial cell numbers do not increase with progressive human diabetic nephropathy, whereas podocyte numbers decrease.PubMedGoogle Scholar
  10. 10.
    Steffes MW, Bilous RW, Sutherland DER, Mauer SM: Cell and matrix components of the glomerular mesangium in type I diabetes mellitus. Diabetes 1992, 41:679–684.PubMedCrossRefGoogle Scholar
  11. 11.
    Sharma K, Ziyadeh FN: The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 1994, 266:F829-F842.PubMedGoogle Scholar
  12. 12.
    Bottinger E, Bitzer M: TGF-beta signaling in renal disease. J Am Soc Nephrol 2002, 13:2600–2610.PubMedCrossRefGoogle Scholar
  13. 13.
    Roberts AB, Piek E, Bottinger EP, et al.: Is Smad3 a major player in signal transduction pathways leading to fibrogenesis? Chest 2001, 120:43S-47S.PubMedCrossRefGoogle Scholar
  14. 14.
    Piek E, Ju W, Heyer J, et al.: Functional characterization of transforming growth factor Beta signaling in Smad2 and Smad3-deficient fibroblasts. J Biol Chem 2001, 276:19945–19953. An elegant study showing the dependence of Smad2 and Smad3 in TGF-â signaling in relation to matrix molecules using fibroblasts from Smad2 and Smad3 knockout mice.PubMedCrossRefGoogle Scholar
  15. 15.
    Tsuchida K-I, Zhu Y, Siva S, et al.: Role of Smad4 on TGF-betainduced extracellular matrix stimulation in mesangial cells. Kidney Int 2003, 63:2000–2009. In this study, we demonstrate that Smad4 is necessary for type I collagen stimulation by TGF-â in mesangial cells.PubMedCrossRefGoogle Scholar
  16. 16.
    Sirard C, Kim S, Mirtsos C, et al.: Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor beta-related signaling. J Biol Chem 2000, 275:2063–2070.PubMedCrossRefGoogle Scholar
  17. 17.
    Chen S, Jim B, Ziyadeh F: Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Sem Nephrol 2003, 23:532–543.CrossRefGoogle Scholar
  18. 18.
    Sharma K, Guo J, Jin Y, Ziyadeh FN: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ induced diabetic mice. Diabetes 1996, 45:522–530.PubMedCrossRefGoogle Scholar
  19. 19.
    Isono M, Chen S, Hong S, Iglesias-de la Cruz M, Ziyadeh F: Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells. Biochem Biophys Res Comm 2002, 296:1356–1365.PubMedCrossRefGoogle Scholar
  20. 20.
    Sharma K, Ziyadeh FN: The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 1994, 266:F829-F842.PubMedGoogle Scholar
  21. 21.
    Sharma K, Ziyadeh F: Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. Sem Nephrol 1997, 17:80–92.Google Scholar
  22. 22.
    Ziyadeh FN, Sharma K, Ericksen M, Wolf G: Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by activation of transforming growth factor-beta. J Clin Invest 1994, 93:536–542.PubMedCrossRefGoogle Scholar
  23. 23.
    Ziyadeh F, Hoffman B, Han D, et al.: Long-term prevention of renal insufficiency excess matrix gene expression and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000, 97:8015–8020. This is the first study showing that an anti-TGF-â approach is beneficial in a model of kidney disease that is similar to a common human condition.PubMedCrossRefGoogle Scholar
  24. 24.
    Benigni A, Zoja C, Corna D, et al.: Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003, 14:1816–1824. Well-performed study showing the added benefit of anti-TGF-â antibodies to ACE inhibitor in a model of chronic diabetic nephropathy.PubMedCrossRefGoogle Scholar
  25. 25.
    Sharma K, Ziyadeh FN, Alzahabi B, et al.: Increased renal production of transforming growth factor-beta 1 in patients with type II diabetes. Diabetes 1997, 46:854–859.PubMedCrossRefGoogle Scholar
  26. 26.
    Iwano M, Kubo A, Nishino T, et al.: Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus. Kidney Int 1996, 49:1120–1126.PubMedCrossRefGoogle Scholar
  27. 27.
    Yamamoto T, Noble NA, Cohen AH, et al.: Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996, 49:461–469.PubMedCrossRefGoogle Scholar
  28. 28.
    Yamamoto T, Nakamura T, Noble NA, et al.: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 1993, 90:1814–1818.PubMedCrossRefGoogle Scholar
  29. 29.
    Yamamoto M, Nakamura H, Yamato M, et al.: Retardation of phenotypic transition of rabbit arterial smooth muscle cells in three-dimensional primary culture. Exp Cell Res 1996, 225:12–21.PubMedCrossRefGoogle Scholar
  30. 30.
    Chaturvedi N, Schalkwijk C, Abrahamian H, et al.: Circulating and urinary transforming growth factor beta1, Amadori albumin, and complications of type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care 2002, 25:2320–2327.PubMedCrossRefGoogle Scholar
  31. 31.
    Houlihan C, Akdeniz A, Tsalamandris C, et al.: Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 2002, 25:1072–1077.PubMedCrossRefGoogle Scholar
  32. 32.
    Sharma K, Eltayeb B, McGowan T, et al.: Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999, 34:818–823.PubMedGoogle Scholar
  33. 33.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456–1462.PubMedCrossRefGoogle Scholar
  34. 34.
    Campistol J, Inigo P, Jimenez W, et al.: Losartan decreases plasma levels of TGF-beta 1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999, 56:714–719.PubMedCrossRefGoogle Scholar
  35. 35.
    Agarwal R, Siva S, Dunn SR, Sharma K: Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-(beta) levels. Am J Kidney Dis 2002, 39:486–492.PubMedCrossRefGoogle Scholar
  36. 36.
    Brenner B, Cooper M: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.PubMedCrossRefGoogle Scholar
  37. 37.
    Riser B, Cortes P, Heilig C, et al.: Cyclic stretching forces selectively up-regulates transforming growth factor-beta isoforms in cultured rat mesangial cells. Am J Pathol 1996, 148:1915–1923.PubMedGoogle Scholar
  38. 38.
    Jafar T, Stark P, Schmid C, et al.: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. Ann Intern Med 2003, 139:244–252.PubMedGoogle Scholar
  39. 39.
    Sharma K, Ziyadeh FN: Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol 1994, 267:F1094-F1001.PubMedGoogle Scholar
  40. 40.
    Park IS, Kiyomoto H, Abboud S, Abboud H: Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes. Diabetes 1997, 46:473–480.PubMedCrossRefGoogle Scholar
  41. 41.
    Fioretto P, Steffes MW, Sutherland DER, et al.: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69–75.PubMedCrossRefGoogle Scholar
  42. 42.
    Okuda S, Nakamura T, Yamamoto T, et al.: Dietary protein restriction rapidly reduces transforming growth factor-beta1 expression in experimental glomerulonephritis. Proc Natl Acad Sci U S A 1991, 88:9765–9769.PubMedCrossRefGoogle Scholar
  43. 43.
    Qin J, Zhang Z, Liu J, et al.: Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int 2003, 64:565–571.PubMedCrossRefGoogle Scholar
  44. 44.
    Flores L, Vidal M, Abian J, et al.: The effects of smoking and its cessation on 8-epi-PGF2alpha and transforming growth factor-beta 1 in Type 1 diabetes mellitus. Diabet Med 2004, 21:285–289.PubMedCrossRefGoogle Scholar
  45. 45.
    Juknevicius I, Segal Y, Kren S, et al.: Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol 2004, 286:F1059-F1062.PubMedCrossRefGoogle Scholar
  46. 46.
    Sharma K, Deelman L, Madesh M, et al.: Involvement of transforming growth factor-(beta) in regulation of calcium transients in diabetic vascular smooth muscle cells. Am J Physiol Renal Physiol 2003, 285:F1258-F1270. This is the first demonstration that altered calcium transients in vascular smooth muscle cells form diabetes may be reversed with anti-TGF-â antibody treatment. In this study, it was also demonstrated that anti-TGF-â antibodies decrease the increased glomerular filtration surface area characteristic of diabetes.PubMedGoogle Scholar
  47. 47.
    Dahly AJ, Hoagland KM, Flasch AK, et al.: Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats. Am J Physiol Regul Integr Comp Physiol 2002, 283:R757-R767.PubMedGoogle Scholar
  48. 48.
    Ledbetter S, Kurtzberg L, Doyle S, Pratt B: Renal fibrosis in mice treated with human recombinant transforming growth factor beta 2. Kidney Int 2000, 58:2367–2376. A fascinating study showing that TGF-â markedly alters the medullary circulation in the mouse kidney.PubMedCrossRefGoogle Scholar
  49. 49.
    Kelly F, Anderson S, Thompson M, et al.: Acute and chronic renal effects of recombinant human TGF-beta2 in the rat. J Am Soc Nephrol 1999, 10:1264–1273.PubMedGoogle Scholar
  50. 50.
    Kuwahara F, Kai H, Tokuda K, et al.: Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002, 106:130–135.PubMedCrossRefGoogle Scholar
  51. 51.
    Roberts A, Vodovotz Y, Roche N, et al.: Role of nitric oxide in antagonistic effects of transforming growth factor-beta and interleukin-1 beta on the beating rate of cultured cardiac myocytes. Mol Endocrinol 1992, 6:1921–1930.PubMedCrossRefGoogle Scholar
  52. 52.
    Sharma K, McCue P, Dunn SR: Diabetic kidney disease in the db/ db mouse. Am J Physiol Renal Physiol 2003, 284:F1138-F1144.PubMedGoogle Scholar
  53. 53.
    Chen S, Iglesias-de la Cruz MC, Jim B, et al.: Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem Biophys Res Commun 2003, 300:16–22.PubMedCrossRefGoogle Scholar
  54. 54.
    Hill C, Flyvbjerg A, Rasch R, et al.: Transforming growth factorbeta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol 2001, 170:647–651.PubMedCrossRefGoogle Scholar
  55. 55.
    Yang Y, Dukhanina O, Tang B, et al.: Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002, 109:1607–1615.PubMedCrossRefGoogle Scholar
  56. 56.
    Ma L, Jha S, Ling H, et al.: Divergent effects of low versus high dose anti-TGF-B antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int 2004, 65:106–115.PubMedCrossRefGoogle Scholar
  57. 57.
    Han D, Hoffman B, Hong S: Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNA in diabetic mice. Am J Physiol 2000, 278:F629-F634.Google Scholar
  58. 58.
    George J, Roulot D, Koteliansky V, Bissell D: In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999, 96:12719–12724.PubMedCrossRefGoogle Scholar
  59. 59.
    Border WA, Noble NA, Yamamoto T, et al.: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992, 360:361–364.PubMedCrossRefGoogle Scholar
  60. 60.
    Bottinger E, Factor V, Tsang M, et al.: The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc Natl Acad Sci U S A 1996, 93:5877–5882.PubMedCrossRefGoogle Scholar
  61. 61.
    Poczatek M, Hugo C, Darley-Usmar V, Murphy-Ullrich J: Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1. Am J Pathol 2000, 157:1353–1363.PubMedGoogle Scholar
  62. 62.
    Mifsud S, Kelly D, Qi W, et al.: Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol 2003, 95:83–91.CrossRefGoogle Scholar
  63. 63.
    McGowan T, Dunn SR, Sharma K: Treatment of db/db mice with pirfenidone leads to improved histology and serum creatinine. J Am Soc Nephrol 2000, 11:A2814.Google Scholar
  64. 64.
    Lasky J, Ortiz L: Antifibrotic therapy for the treatment of pulmonary fibrosis. Am J Med Sci 2001, 322:213–221.PubMedCrossRefGoogle Scholar
  65. 65.
    Iyer SN, Gurujeyalakshmi G, Giri S.: Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999, 291:367–373.PubMedGoogle Scholar
  66. 66.
    Hewitson T, Kelynack K, Tait M, et al.: Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 2001, 14:453–460.PubMedGoogle Scholar
  67. 67.
    Shimizu T, Kuroda T, Hata S, et al.: Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 1998, 54:99–109.PubMedCrossRefGoogle Scholar
  68. 68.
    Al-Bayati M, Xie Y, Mohr F, et al.: Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem Pharmacol 2002, 64:517–525.PubMedCrossRefGoogle Scholar
  69. 69.
    Giri S, Al-Bayati M, Du X, et al.: Amelioration of doxorubicininduced cardiac and renal toxicity by pirfenidone in rats. Cancer Chemother Pharmacol 2004, 53:141–150.PubMedCrossRefGoogle Scholar
  70. 70.
    Shihab F, Bennett W, Yi H, Andoh T: Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2002, 2:111–119.PubMedCrossRefGoogle Scholar
  71. 71.
    Miric G, Dallemagne C, Endre Z, et al.: Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001, 133:687–694.PubMedCrossRefGoogle Scholar
  72. 72.
    Raghu G, Johnson WC, Lockhart D, Mageto Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999, 159:1061–1069.PubMedGoogle Scholar
  73. 73.
    Gahl W, Brantly M, Troendle J, et al.: Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 2002, 76:234–242.PubMedCrossRefGoogle Scholar
  74. 74.
    Taniyama M, Ohbayashi S, Narita M, et al.: Pharmacokinetics of an antifibrotic agent, pirfenidone, in hemodialysis patients. Eur J Clin Pharmacol 1997, 52:77–78.PubMedCrossRefGoogle Scholar
  75. 75.
    Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117–124.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Tracy A. McGowan
  • Yanqing Zhu
  • Kumar Sharma
    • 1
  1. 1.Dorrance Hamilton Research Laboratories, Division of Nephrology,Center for Diabetic Kidney DiseaseThomas Jefferson University HospitalPhiladelphiaUSA

Personalised recommendations